| Income Statement | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Sales | 19,667 | 20,005 | ||
| Cost of goods sold | 4,409 | 6,727 | ||
| Gross profit | 15,258 | 13,278 | ||
| Research and development expense | 16,053 | 17,570 | ||
| Legal and professional fees | 155,068 | 187,573 | ||
| Consulting fees | 1,568,563 | 7,322 | ||
| Salaries, wages, and related costs | 105,280 | 104,175 | ||
| General and administrative | 129,815 | 100,676 | ||
| Operating expenses | 1,974,779 | 417,316 | ||
| Operating income (loss) | -1,959,521 | -404,038 | ||
| Interest expense, nonoperating | 106,346 | 74,013 | ||
| Change in fair value of derivative liabilities | 11,385 | -5,921 | ||
| Loss on derivative liabilities | 19,055 | 20,415 | ||
| Nonoperating income (expense) | -75,906 | -59,519 | ||
| Income (loss) from continuing operations before income taxes, noncontrolling interest | -2,035,427 | -463,557 | ||
| Provision for income taxes | - | 800 | ||
| Net loss | -2,035,427 | -464,357 | ||
| Loss attributable to non-controlling interest | -1,027,893 | -74,311 | ||
| Net income (loss) attributable to parent | -1,007,534 | -390,046 | ||
| Basic eps | 0 | 0 | ||
| Diluted eps | 0 | 0 | ||
| Basic average shares | 4,913,103,351 | 4,511,799,474 | ||
| Diluted average shares | 4,913,103,351 | 4,511,799,474 | ||
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (TSOI)
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (TSOI)